Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 19/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4370562 | 0.91 | HTR1A (0.62) | HTR1ASLC6A4DRD2CYP3A4CYP2C8 | |
| SCHEMBL4363257 | 0.89 | HTR1A (0.73) | HTR1ASLC6A4DRD2CYP3A4CYP2C8 | |
| SCHEMBL4363135 | 0.87 | HTR1A (0.50) | HTR1ASLC6A4 | |
| SCHEMBL6630467 | 0.85 | HTR1A (0.81) | HTR1ASLC6A4DRD2CYP3A4CYP2C8 | |
| SCHEMBL6629168 | 0.84 | HTR1A (0.82) | HTR1ASLC6A4DRD2CYP3A4CYP2C8 | |
| SCHEMBL4365101 | 0.82 | HTR1A (0.48) | HTR1ASLC6A4DRD2DRD4DRD3 | |
| SCHEMBL6650469 | 0.82 | HTR1A (0.60) | HTR1ASLC6A4DRD2CYP3A4CYP2C8 | |
| SCHEMBL6903037 | 0.81 | HTR1A (0.76) | HTR1ASLC6A4DRD2CYP3A4CYP2C8 | |
| SCHEMBL4365868 | 0.79 | HTR1A (0.67) | HTR1ASLC6A4DRD2CYP3A4CYP2C8 | |
| SCHEMBL4363811 | 0.79 | HTR1A (0.66) | HTR1ASLC6A4DRD2CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939877-B2 | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2005-09-06 | — | — | US | claimed |
| EP-1537120-A1 | ANTIDEPRESSANT PIPERIDINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | Wyeth, A Corporation of the State of Delaware (US) | 2005-06-08 | — | — | EP | claimed |
| US-20040147523-A1 | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans | WYETH | 2004-07-29 | — | — | US | claimed |
| WO-2004024733-A1 | ANTIDEPRESSANT PIPERIDINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2004-03-25 | — | — | WO | claimed |
| US-20090042895-A1 | Antidepressant Piperidine Derivatives of Heterocycle-Fused Benzodioxans | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-7479500-B2 | Antidepressant piperidine derivatives of heterocyclefused benzodioxans | WYETH (US) | 2009-01-20 | — | — | US | disclosed |
| US-20050228009-A1 | Antidepressant piperidine derivatives of heterocyclefused benzodioxans | WYETH (US) | 2005-10-13 | — | — | US | disclosed |
| US-6939877-B2 | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1537120-A1 | ANTIDEPRESSANT PIPERIDINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | Wyeth, A Corporation of the State of Delaware (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040147523-A1 | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans | WYETH | 2004-07-29 | — | — | US | disclosed |
| WO-2004024733-A1 | ANTIDEPRESSANT PIPERIDINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228009-A1 | Antidepressant piperidine derivatives of heterocyclefused benzodioxans | HTR5A, OPRD1, DRD2 | HTR1A 53/4885SLC6A4 166/4885DRD2 3/4885 |
| US-20040147523-A1 | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans | HTR5A, OPRD1, CRH | HTR1A 44/4885SLC6A4 172/4885DRD2 4/4885 |
| US-20090042895-A1 | Antidepressant Piperidine Derivatives of Heterocycle-Fused Benzodioxans | HTR5A, OPRD1, CRH | HTR1A 39/4885SLC6A4 155/4885DRD2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.